A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas

被引:26
作者
Soslow, RA
Carlson, DL
Horenstein, MG
Osborne, MP
机构
[1] Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Dept Pathol, New York, NY 10021 USA
[2] Univ S Alabama, Dept Pathol, Mobile, AL 36688 USA
[3] Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Dept Surg, New York, NY USA
[4] Strang Canc Prevent Ctr, New York, NY USA
关键词
breast cancer; cell cycle; ductal; histologic subtypes; lobular;
D O I
10.1023/A:1006479113769
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Infiltrating lobular carcinoma (ILC) and infiltrating ductal carcinoma (IDC) are similar in many respects and their histologic features occasionally overlap. Despite the many similarities, some clinical follow-up data and the patterns of metastasis suggest that ILC and IDC are biologically distinct. Unfortunately, most breast cancer research has focused almost exclusively on the ductal subtype or has not stressed the biologic or molecular genetic distinctions between breast carcinoma subtypes. Several reports have suggested the possibility that ILCs and IDCs differ with respect to expression of antigens involved in proliferation and cell cycle regulation. Therefore, we undertook an immunohistochemical evaluation of cell cycle related antigens in ILCs, including histologic variants thought to represent aggressive neoplasms, and IDCs matched for histologic grade (Modified Bloom-Richardson Grade I). We believe that different antigent expression profiles could elucidate the biological distinctiveness of breast carcinoma subtypes and possibly provide diagnostically relevant information. We studied the expression of the following antigents in 28 archived, formalin-fixed ILCs and 34 well-differentiated IDCs: estrogen receptor (ER), progesterone receptor (PR), Her 2-neu, mib-1, cyclin D1, p27, p53, mdm-2 and bcl-2. 94% of ILCs and 100% of IDCs expressed ER; 75% of ILCs and 76% of IDCs expressed PR; 4% of ILCs and 13% of IDCs expressed c cerb B-2; ILCs and IDCs both expressed mib-1 in approximately 10% of lesional cells; 82% of ILCs and 54% of IDCs expressed cyclin D1; 90% of ILCs and 83% IDCs expressed p27 strongly; 4% of ILCs and 4% of IDCs expressed p53, 25% of ILCs and 33% of IDCs expressed mdm-2; 96% of ILCs and 100% of IDCs expressed bcl-2. None of the apparent differences were statistically significant. The ILC variants demonstrated immunophenotypes that were essentially similar to ILCs of the usual type. We conclude that ILCs and well-differentiated IDCs show similar proliferation and cell cycle control antigen profiles. Despite their unusual histologic features, most ILC variants appear to maintain a characteristic ILC immunophenotype.
引用
收藏
页码:161 / 170
页数:10
相关论文
共 53 条
[1]   Cellular proliferation in breast ductal infiltrating carcinoma - Correlation with clinical and histopathological variables [J].
Aranda, FI ;
Laforga, JB .
PATHOLOGY RESEARCH AND PRACTICE, 1997, 193 (10) :683-688
[2]   P53 AND C-ERBB-2 PROTEIN EXPRESSION IN BREAST CARCINOMAS - AN IMMUNOHISTOCHEMICAL STUDY INCLUDING CORRELATIONS WITH RECEPTOR STATUS, PROLIFERATION MARKERS, AND CLINICAL STAGE IN HUMAN BREAST-CANCER [J].
BARBARESCHI, M ;
LEONARDI, E ;
MAURI, FA ;
SERIO, G ;
PALMA, PD .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1992, 98 (04) :408-418
[3]  
Bentz JS, 1998, MODERN PATHOL, V11, P814
[4]  
Berx G, 1996, ONCOGENE, V13, P1919
[5]  
BHARGAVA V, 1994, AM J PATHOL, V145, P535
[6]   Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables [J].
Binder, C ;
Marx, D ;
Overhoff, R ;
Binder, L ;
Schauer, A ;
Hiddemann, W .
ANNALS OF ONCOLOGY, 1995, 6 (10) :1005-1010
[7]  
BLANCO G, 1984, ANTICANCER RES, V4, P383
[8]  
BORST MJ, 1993, SURGERY, V114, P637
[9]  
Courjal F, 1996, INT J CANCER, V69, P247
[10]  
Cserni G, 1999, J SURG ONCOL, V70, P217, DOI 10.1002/(SICI)1096-9098(199904)70:4<217::AID-JSO3>3.3.CO